Features an ATP solution to allow for efficiency
Systech, a Markem-Imaje solutions brand that offers brand protection via packaging serialization, has partnered with software provider Spherity to offer a solution for promoting compliance with the Drug Supply Chain Security Act (DSCSA), part of which requires the verification of trading partners. Both organizations are members of the Open Credentialing Initiative (OCI), a collaborative, non-profit initiative formed by a group of trading partners, solution providers, and standard organizations to support the pharma industry in adopting credentialing and digital wallet technologies to enhance supply chain security.
Incorporating an electronic system to trace prescription drug products is the last phase in the DSCSA program, which requires compliance by November 2023. Together with Spherity, Systech is introducing an Authorized Trading Partner (ATP) solution that, according to the parties, provides efficient and error-free accreditation of partners within the pharma supply chain, following manufacture. Verifying supply chain partners between the point of creation and point of dispensation is an extra layer in protecting the end consumer.
“Our goal always, is to partner with our pharmaceutical customers on their compliance journey,” says David DeJean, vice president of customer success and business development, Systech solutions by Markem-Imaje. “By combining Spherity’s subject expertise with our leadership in traceability, we provide a swift and easy-to-integrate route to best practice compliance for our customers. Data is the key ingredient for almost all aspects of DSCSA compliance. Our role is to provide a solution for secure and reliable capture, use and storage of that data—so that our customers can focus on their core operations.”
For more information on DSCSA, be sure to visit Pharma Commerce’s June issue.
The Digital Transformation Reshaping Hospitals and Medication Management
January 20th 2025Despite challenges surrounding communication overload, drug shortages, and cybersecurity risks, this term is revolutionizing medication management and patient care through the use artificial intelligence and predictive forecasting.
Newron, Myung In Pharm Form Partnership Centered Around Treating Schizophrenia in South Korea
January 14th 2025The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.